Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Solid Tumors
- Epithelial Ovarian Cancer
- Malignant Melanoma
- Squamous Cell Cancer of Head and Neck
- Triple -Negative Breast Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study will involve treatment with pembrolizumab, tests and procedures done for safety, and the collection of archival tumor tissue, fresh tumor biopsies, and blood samples for biomarker research (including genetic testing).
This study will involve treatment with pembrolizumab, tests and procedures done for safety, and the collection of archival tumor tissue, fresh tumor biopsies, and blood samples for biomarker research (including genetic testing).
Tracking Information
- NCT #
- NCT02644369
- Collaborators
- Merck Sharp & Dohme Corp.
- Investigators
- Principal Investigator: Lillian Siu, M.D. Princess Margaret Cancer Centre
Get Well Soon